Eppendorf Award for Young European Investigators 2015: Call for Entries!
News Oct 31, 2014
Until 15 January 2015, young researchers working in Europe who are not older than 35 years are invited to apply for the Eppendorf Award for Young European Investigators. This highly prestigious prize acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.
In 2015 the Eppendorf Award for Young European Investigators celebrates 20 years. To mark this milestone, Eppendorf has increased the prize money to 20,000 euros.
The winner is selected by an independent expert committee chaired by Reinhard Jahn (Max Planck Institute for Biophysical Chemistry, Göttingen, Germany).
The Award winner 2015 will receive:
• Prize money of 20,000 EUR
• An invitation to the prize ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany, on June 25, 2015
• An invitation to visit Eppendorf AG in Hamburg, Germany
• Coverage of his/her work by Nature in print and online (including a podcast)
Full details on the Eppendorf Award, the selection criteria and past Award winners can be found at www.eppendorf.com/award. Here potential prize winners will find all relevant information for a successful application.
Only online applications are accepted. The official online registration portal will accept applications as of October 1, 2014 at www.eppendorf.com/award/application.
The Eppendorf Award for Young European Investigators is presented in partnership with Nature.
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE